Featured Research

from universities, journals, and other organizations

Study examines new class of anticoagulants for VTE prevention, treatment

Date:
December 11, 2013
Source:
University of Michigan Health System
Summary:
A federal award supports the study of a new class of drugs to prevent dangerous blood clots.

The University of Michigan has been awarded $1.7 million to collaborate with GlycoMimetics, Inc., to study a new class of anticoagulants to help millions of Americans at risk or venous thromboembolic disease (VTE), a serious blood-clotting disorder.

The National Heart Lung and Blood Institute is supporting the three-year clinical trial of GMI-1271, an E-selectin antagonist that preliminary data shows prevents blood clot formation and reduces thrombus weight by 50-60 percent.

Co-principal investigators at the U-M are Suman Sood, M.D., a hematologist at the University of Michigan Comprehensive Cancer Center, and Thomas Wakefield, M.D., head of vascular surgery at the U-M Frankel Cardiovascular Center.

VTE, which can happen after a major operation, or severe illness such as heart attacks, stroke and some cancers, refers to both pulmonary embolism and deep vein thrombosis (DVT), blood clots that form in large veins of the legs. The clots become dangerous when they break loose and affect blood flow to the heart and lungs.

A mainstay of VTE prevention and treatment are anticoagulants that reduce blood clotting. But the medicines are associated with a significant risk of hemorrhage and for the most part do not decrease the inflammation that comes with VTE.

"The use of E-selection inhibition has a high therapeutic potential to decrease both thrombosis and its harmful inflammatory effects," says Sood.

GMI-1271 inhibits the cell-cell interactions that provide the scaffolding for blood clots to form. The compound is in the pipeline of drugs developed by GlycoMimetics, Inc., a clinical stage biotechnology company.

"We hypothesize that use of an E-selection inhibitor in patients with acute DVT, either alone or in combination with traditional anticoagulants, may lead to a greater thrombus resolution, higher rates of preserved valve competence, reduced pain and swelling and improved quality of life," says Wakefield.

Enrollment in the phase 1 clinical trial at the U-M is expected to begin in mid-2014 and to include healthy volunteers and those with calf level DVT.


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University of Michigan Health System. "Study examines new class of anticoagulants for VTE prevention, treatment." ScienceDaily. ScienceDaily, 11 December 2013. <www.sciencedaily.com/releases/2013/12/131211093620.htm>.
University of Michigan Health System. (2013, December 11). Study examines new class of anticoagulants for VTE prevention, treatment. ScienceDaily. Retrieved September 22, 2014 from www.sciencedaily.com/releases/2013/12/131211093620.htm
University of Michigan Health System. "Study examines new class of anticoagulants for VTE prevention, treatment." ScienceDaily. www.sciencedaily.com/releases/2013/12/131211093620.htm (accessed September 22, 2014).

Share This



More Health & Medicine News

Monday, September 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com
Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins